NCT01569815View on ClinicalTrials.gov

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Mild and Moderate Renal Impairment
Interventions
DRUG

LCZ696

LCZ696 400 mg once daily

Trial Locations (3)

41460

Novartis Investigative Site, Neuss

117292

Novartis Investigative Site, Moscow

Unknown

Novartis Investigative Site, Belgrade

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY